MRI-Based Brain Connectivity Networks Predict Atrophy Progression in Parkinson's Disease, Study Finds

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-06-28 14:30 GMT   |   Update On 2024-06-28 16:36 GMT
Advertisement

Italy: Cutting-edge research utilizing MRI technology has uncovered promising insights into predicting patterns of atrophy progression in Parkinson's disease (PD) through brain connectivity networks. The study, published in the journal Radiology, marks a significant advancement in understanding neurodegenerative processes associated with PD.

The researchers revealed that MRI illuminates the structural and functional organization of the brain -- thus helping clinicians predict the progression of Parkinson's disease in patients in its early stages.

Advertisement

They reported that Parkinson's "disease exposure" at one and two years correlated with white matter atrophy at two years and three years after baseline imaging.

The study stated that "brain connectome, both functional and structural, showed the potential to predict progression of gray matter (GM) alteration in patients with mild Parkinson's disease."

Parkinson's disease, a chronic and progressive neurological disorder, is known to manifest through symptoms such as tremors, stiffness, slowness of movement, and cognitive decline. Understanding the underlying mechanisms of brain atrophy progression is crucial for developing targeted therapies to slow disease progression and improve the quality of life for patients. Considering this, Massimo Filippi, University Hospital Maggiore della Carità, Novara, Italy, and colleagues aimed to assess the functional and structural connectivity of brain regions in healthy controls and its relationship with the spread of GM atrophy in patients with mild PD.

For this purpose, the researchers conducted a prospective study comprising participants with mild PD and controls recruited from a single center between 2012 and 2023. Participants diagnosed with PD underwent three-dimensional T1-weighted brain MRI scans to assess regional gray matter atrophy at baseline and annually for three years.

In healthy controls, structural and functional brain connectomes were generated using diffusion tensor imaging and resting-state functional MRI. Disease exposure (DE) indexes for each brain region were defined based on the connectivity patterns of all linked regions in the healthy connectome and the extent of atrophy observed in PD participants' connected regions. Partial correlations were examined between the structural and functional DE indexes of each GM region at one- or two-year follow-up and the progression of atrophy at a two- or three-year follow-up. Prediction models for atrophy progression at two- or three-year follow-ups were developed using exhaustive feature selection methods.

The study led to the following findings:

  • The study included 86 participants with mild PD (mean age at MRI, 60 years ± 8; 48 male) and 60 healthy controls (mean age at MRI, 62 years ± 9; 31 female).
  • DE indexes at 1 and 2 years correlated with atrophy at 2 and 3 years (r range, 0.22–0.33).
  • Models including DE indexes predicted GM atrophy accumulation over three years in the right caudate nucleus and some frontal, parietal, and temporal brain regions (R2 range, 0.40–0.61).

"The functional and structural organization of the brain connectome plays a role in atrophy progression in the early stages of Parkinson's disease," the researchers wrote.

Reference:

https://doi.org/10.1148/radiol.232454


Tags:    
Article Source : Radiology journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News